P
ParcelBio
Developing a programmable technique for safely and accurately delivering mRNA to various cell types within the body
About ParcelBio
Based in San Francisco, ParcelBio is a biotechnology company established in 2023, focused on advancing the delivery of messenger RNA (mRNA) therapeutics. The company was co-founded by CEO David Weinberg and Chief Scientific Officer (CSO) Chris Carlson. Weinberg's background includes a Ph.D. from MIT and roles as VP of RNA Platform at Orbital Therapeutics and Sr. Director of Molecular Research at Freenome. Carlson holds a Ph.D. from UCSF and was previously a scientist at Orbital Therapeutics, contributing to patents on therapeutic RNA stabilization.
ParcelBio addresses a core challenge in the field of RNA therapeutics: the efficient and safe delivery of mRNA to specific cells beyond vaccine applications. The company is developing a proprietary, nanoparticle-free technology called STAmP (Stabilization and Targeting by Annealing mRNA to ParcelOligos). This platform uses 'ParcelOligos' to stabilize the mRNA molecule and incorporates interchangeable 'keys'—naturally occurring molecules—that bind to specific 'locks' on target cells, enabling precise delivery. This method is designed to produce more targeted, potent, and durable RNA therapeutics compared to traditional approaches.
The company's business model centers on leveraging its STAmP platform to develop treatments for conditions with significant unmet needs. Initially, ParcelBio is targeting kidney disorders, chronic liver diseases, and immune system dysregulation. The company also plans to form collaborations and partnerships with other pharmaceutical and biotechnology firms to apply its technology to enhance mRNA vaccines and deliver CRISPR gene-editing tools. ParcelBio is a privately held, venture-backed company that has participated in the Y Combinator accelerator program and secured seed funding from investors including Ritual Capital, 468 Capital, and Alumni Ventures.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- San Francisco, United States
- Employees
- 7
- Open positions
- 1
- Dealroom signal
- 76.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Precision Medicine, RNA, Biotech and Pharma, YC W24, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2026 | $13M | $52M | General Catalyst · Metaplanet · Breyer Capital · Y Combinator | ↗ |
| SEED✓Equity / VC | Mar 2024 | $125K | $500K | Y Combinator | ↗ |
Growth signals
Latest recorded traffic for ParcelBio is 310 monthly website visits, down 64.4% over the last three months. ParcelBio's team grew 16.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Y Combinator
Breyer Capital
General Catalyst
Metaplanet
ZAKA VC
Surge Point Capital
Other known investors2 additional known investors
North South Ventures
Pioneer Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ParcelBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ParcelBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.